Elisabeth Turpin

Summary

Country: France

Publications

  1. pmc The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma
    Ghada Kchour
    Department of Biology, Faculty of Sciences, Lebanese University, Hadath, Lebanon
    Retrovirology 10:91. 2013
  2. pmc Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010

Collaborators

  • Ghada Kchour
  • Hugues De The
  • Jacqueline Lehmann-Che
  • Mohamad Ezzedine
  • Abbas Shirdel
  • Olivier Hermine
  • Rahim Rezaee
  • Mahmoud Mahmoudi
  • Fadwa Berry
  • Akram Ghantous
  • Roudaina Nasser
  • Ali Bazarbachi
  • Hiba El Hajj
  • Mohamad Mehdi Kooshyar
  • Zeina Dassouki
  • Hossein Rahimi
  • Reza Farid
  • Mahdi Tarhini
  • Mohamad Mortada
  • Houshang Rafatpanah
  • Ardeshir Ghavamzadeh
  • Christos Sotiriou
  • Sylvie Giacchetti
  • Louis Fran├žois Plassa
  • Lajos Pusztai
  • Fabrice Andre
  • Christine Desmedt
  • Michel Marty
  • Marc Espie
  • Chafika Mazouni
  • Martine Piccart
  • Philippe Bertheau
  • W Fraser Symmans

Detail Information

Publications3

  1. pmc The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma
    Ghada Kchour
    Department of Biology, Faculty of Sciences, Lebanese University, Hadath, Lebanon
    Retrovirology 10:91. 2013
    ..The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN...
  2. pmc Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010
    ..The latter allowed very high levels of pCR in triple-negative tumors. Thus, our data strongly suggest that cyclophosphamide dose intensification in ER(-) p53-mutated breast cancer patients could significantly improve their response...